The market access landscape
moves fast. Read faster.
PBM reform, formulary shifts, ICER assessments, 340B policy, biosimilar dynamics, and pricing intelligence — synthesized weekly into one 15-minute read with competitive analysis and strategic implications.
Six coverage domains.
One integrated view.
Every week we monitor 30+ sources across the market access landscape and distill what matters into competitive intelligence — not summaries, not press releases, but strategic analysis of who wins and who loses.
Policy & Legislation
PBM reform, IRA implementation, MFN proposals, OTC switches, executive orders — with analysis of downstream impact on payer strategy and manufacturer contracting.
Formulary & Coverage
PBM exclusion lists, tier changes, prior authorization shifts, step therapy requirements, Medicare Part D design changes — the decisions that determine patient access.
Pricing & Reimbursement
IRA negotiated prices, WAC trends, gross-to-net dynamics, site-of-care economics, ASP reimbursement, and international reference pricing developments.
340B Program
Contract pharmacy disputes, rebate model litigation, state access laws, covered entity strategies, and the HRSA-to-CMS oversight transfer — the most contested territory in drug pricing.
Biosimilar Dynamics
Launch economics, PBM private-label strategies, interchangeability impact, payer adoption patterns, and the collision between biosimilar competition and government-set pricing.
Value Assessment
ICER evidence reports, health benefit price benchmarks, budget impact analyses, QALY debates, and how value assessments shape real-world coverage decisions.
This week’s digest
Every edition includes top story deep-dives, categorized intelligence briefs, a data snapshot, and a competitive positioning heatmap.
The Consolidated Appropriations Act of 2026 delivers the most significant PBM reform in a decade, delinking Part D compensation from rebates effective 2028. Meanwhile, a federal court vacated the 340B Rebate Pilot and ICER published its cytisinicline value assessment ahead of a June PDUFA — pricing corridors that will test launch discipline in a cost-sensitive category…
Built for the people who
build access strategies
- → Market access and HEOR directors at pharmaceutical manufacturers who need to track PBM shifts, ICER benchmarks, and competitor coverage wins to inform payer value dossiers and launch pricing
- → Formulary and pharmacy directors at health plans, PBMs, and IDNs who manage coverage decisions across specialty, biosimilar, and government-negotiated categories
- → Market access consultants at advisory firms who need weekly competitive intelligence to support client pricing, reimbursement, and payer engagement strategy
- → Specialty pharmacy executives navigating biosimilar transitions, 340B contract dynamics, and limited distribution network changes
- → Government affairs and policy teams tracking legislative and regulatory developments across PBM reform, 340B, IRA implementation, and drug pricing proposals
What we’ve been tracking
15 minutes a week.
Every development that
affects access strategy.
Free weekly digest delivered Friday mornings. Sourced, analytical, written for professionals who make pricing, coverage, and reimbursement decisions.
No spam. Unsubscribe anytime.
Drug Channels Institute · AJMC · ICER · 340B Report · Pharmaceutical Commerce · Managed Healthcare Executive · Formulary Watch · FiercePharma · BioPharma Dive · STAT News · CMS · HRSA · FDA · Company SEC filings · PBM formulary updates · PSG Consults · DLA Piper · Sidley Austin · Congressional Budget Office · State legislative databases